The GTT indicated significantly lower blood glucose AUC in Donor+Cas9 treated mice compared to Saline and Donor groups at 8, 16, and 24 weeks post-injection, with levels comparable to non-treated mice fed with normal fat diet (Normal Diet) at matching time points
Your prescriber works with you to establish a dosing schedule and can provide guidance on reminders, adjustments, or genetic insights through the Precision Peptide Genetic Test to ensure your therapy stays effective and your schedule stays consistent
Severe cases may cause fainting (syncope), which requires immediate medical evaluation
GLP-1s have been approved for diabetes, weight loss, cardiovascular disease risk reduction, sleep apnea, chronic kidney disease and metabolic dysfunction-associated steatohepatitis (which used to be called nonalcoholic fatty liver disease)
Simple actions like eating or lying down can trigger symptoms, making it hard to enjoy meals or rest properly